Breakthrough SARS-CoV-2 infections among recipients of tixagevimab-cilgavimab prophylaxis: A citywide real-world effectiveness study.
Transpl Infect Dis
; 26(1): e14194, 2024 Feb.
Article
in En
| MEDLINE
| ID: mdl-37987112
Key words
Full text:
1
Database:
MEDLINE
Main subject:
COVID-19
Limits:
Humans
/
Middle aged
Language:
En
Year:
2024
Type:
Article